Aagami receives extension from Nose to brain delivery Client developing drugs targeting Frontotemporal Dementia and other neurodegenerative diseases

Published : 10 Jan 2024

We are pleased to announce that Aagami has received contract extension from its Japan and US based client. 

 

Client is a nose to brain [NtoB] delivery (intra-nasal and bypassing the blood brain barrier) technology development company, with special focus on Frontotemporal Dementia. 

 

Client’s assets target a US$24+ Billion market and fulfills a high unmet need in the following neurodegenerative diseases:

  • FTD-Frontotemporal Dementia (FDA granted Orphan Drug Designation to one asset)
  • Alzheimer’s disease, Dementia with Lewy Bodies 
  • Parkinson's disease

Medilabo is looking for investors and strategic partners. If you would like to know more about this, please contact us

×
Twitter